Specific Role of Antengene's AI R&D Department in the Layout of the TCE Platform

According to collected information, Antengene’s AI R&D department plays a key enabling role in the layout of the TCE platform, mainly reflected in the following aspects [1][2][3]:

In early 2025, Antengene announced the official establishment of an AI R&D department and deployed Deepseek technology to accelerate the layout of its second-generation T-cell engager (TCE) platform [1][2]. This strategic move made Antengene a representative enterprise in the Biotech transformation field, with its annual stock price increasing by 483%, reflecting the market’s recognition of its AI transformation strategy [1].

The specific functions of the AI R&D department include:

• Accelerate drug discovery
  : Optimize target selection and validation processes through AI technology to shorten early discovery time
• Molecular design and optimization
  : Use deep learning models to directly generate candidate molecular structures and predict activity and toxicity
• Reduce R&D costs
  : According to industry data, AI technology can reduce early drug discovery costs to 1/200 of traditional methods [4]
• Improve R&D efficiency
  : AI technology can shorten the time required for early drug discovery to 1/3 of traditional methods [4]

Antengene’s self-developed AnTenGager™ platform has a “2+1” bivalent binding structure, which can target low-expression targets, while integrating steric hindrance shielding technology and CD3 antibody sequences with fast binding/dissociation kinetics [2][3]. The AI R&D department provided key support in the following aspects:

• Optimize molecular structure design
  : Optimize the “2+1” architecture through AI algorithms to enhance the ability to target low-expression targets
• Enhance safety
  : AI-assisted design reduces the risk of cytokine release syndrome (CRS) and “hook effect”
• Improve efficacy
  : Achieve a higher therapeutic index through steric hindrance shielding technology

Antengene not only built its own AI team but also established cooperation with external AI drug R&D enterprises:

• Cooperation with XtalPi
  : Use artificial intelligence to accelerate the drug R&D process [5]
• Cooperation with Insilico Medicine
  : Insilico Medicine’s protein dynamic simulation technology has been applied to Antengene’s drug pipeline development, with a total transaction order exceeding 100 million US dollars [4]

Empowered by AI, Antengene’s TCE platform has made significant progress:

• ATG-201 (CD3xCD19 bispecific antibody)
  : Plans to submit an IND application for autoimmune indications in the second half of 2025
• Platform application scope
  : Covers multiple indications such as autoimmune diseases, solid tumors, and hematological tumors

Antengene’s AI R&D department has formed a complete AI drug R&D system through the deployment of Deepseek technology and the establishment of external cooperation. The department plays a core role in key links such as target discovery, molecular design, and safety optimization of the TCE platform, effectively accelerating the R&D process of the AnTenGager platform, reducing R&D risks and costs, and promoting the company to achieve differentiated competition in the innovative drug field.